Literature DB >> 34465587

Polygenic Risk Score Improves Risk Stratification and Prediction of Subsequent Thyroid Cancer after Childhood Cancer.

Nan Song1,2, Qi Liu3, Yutaka Yasui1, Zhaoming Wang4, Carmen L Wilson1, Yadav Sapkota1, Matthew J Ehrhardt1, Todd M Gibson5, Lindsay M Morton5, Stephen J Chanock5, Joseph P Neglia6, Michael A Arnold7, J Robert Michael1, Alexander M Gout1, Heather L Mulder1, John Easton1, Smita Bhatia8, Gregory T Armstrong1, Jinghui Zhang1, Angela Delaney1, Melissa M Hudson1, Leslie L Robison1.   

Abstract

BACKGROUND: Subsequent thyroid cancer (STC) is one of the most common malignancies in childhood cancer survivors. We aimed to evaluate the polygenic contributions to STC risk and potential utility in improving risk prediction.
METHODS: A polygenic risk score (PRS) was calculated from 12 independent SNPs associated with thyroid cancer risk in the general population. Associations between PRS and STC risk were evaluated among survivors from St. Jude Lifetime Cohort (SJLIFE) and were replicated in survivors from Childhood Cancer Survivor Study (CCSS). A risk prediction model integrating the PRS and clinical factors, initially developed in SJLIFE, and its performance were validated in CCSS.
RESULTS: Among 2,370 SJLIFE survivors with a median follow-up of 28.8 [interquartile range (IQR) = 21.9-36.1] years, 65 (2.7%) developed STC. Among them, the standardized PRS was associated with an increased rate of STC [relative rate (RR) = 1.57; 95% confidence interval (CI) = 1.24-1.98; P < 0.001]. Similar associations were replicated in 6,416 CCSS survivors, among whom 121 (1.9%) developed STC during median follow-up of 28.9 (IQR = 22.6-34.6) years (RR = 1.52; 95% CI = 1.25-1.83; P < 0.001). A risk prediction model integrating the PRS with clinical factors showed better performance than the model considering only clinical factors in SJLIFE (P = 0.004, AUC = 83.2% vs. 82.1%, at age 40), which was further validated in CCSS (P = 0.010, AUC = 72.9% vs. 70.6%).
CONCLUSIONS: Integration of the PRS with clinical factors provided a statistically significant improvement in risk prediction of STC, although the magnitude of improvement was modest. IMPACT: PRS improves risk stratification and prediction of STC, suggesting its potential utility for optimizing screening strategies in survivorship care. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34465587      PMCID: PMC8568663          DOI: 10.1158/1055-9965.EPI-21-0448

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  31 in total

1.  The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl.

Authors:  Meiko Takahashi; Vladimir A Saenko; Tatiana I Rogounovitch; Takahisa Kawaguchi; Valentina M Drozd; Hisako Takigawa-Imamura; Natallia M Akulevich; Chanavee Ratanajaraya; Norisato Mitsutake; Noboru Takamura; Larisa I Danilova; Maxim L Lushchik; Yuri E Demidchik; Simon Heath; Ryo Yamada; Mark Lathrop; Fumihiko Matsuda; Shunichi Yamashita
Journal:  Hum Mol Genet       Date:  2010-03-29       Impact factor: 6.150

2.  Survival model predictive accuracy and ROC curves.

Authors:  Patrick J Heagerty; Yingye Zheng
Journal:  Biometrics       Date:  2005-03       Impact factor: 2.571

3.  A genome-wide association study yields five novel thyroid cancer risk loci.

Authors:  Julius Gudmundsson; Gudmar Thorleifsson; Jon K Sigurdsson; Lilja Stefansdottir; Jon G Jonasson; Sigurjon A Gudjonsson; Daniel F Gudbjartsson; Gisli Masson; Hrefna Johannsdottir; Gisli H Halldorsson; Simon N Stacey; Hannes Helgason; Patrick Sulem; Leigha Senter; Huiling He; Sandya Liyanarachchi; Matthew D Ringel; Esperanza Aguillo; Angeles Panadero; Enrique Prats; Almudena Garcia-Castaño; Ana De Juan; Fernando Rivera; Li Xu; Lambertus A Kiemeney; Gudmundur I Eyjolfsson; Olof Sigurdardottir; Isleifur Olafsson; Hoskuldur Kristvinsson; Romana T Netea-Maier; Thorvaldur Jonsson; Jose I Mayordomo; Theo S Plantinga; Hannes Hjartarson; Jon Hrafnkelsson; Erich M Sturgis; Unnur Thorsteinsdottir; Thorunn Rafnar; Albert de la Chapelle; Kari Stefansson
Journal:  Nat Commun       Date:  2017-02-14       Impact factor: 14.919

4.  Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study.

Authors:  Parveen Bhatti; Lene H S Veiga; Cécile M Ronckers; Alice J Sigurdson; Marilyn Stovall; Susan A Smith; Rita Weathers; Wendy Leisenring; Ann C Mertens; Sue Hammond; Debra L Friedman; Joseph P Neglia; Anna T Meadows; Sarah S Donaldson; Charles A Sklar; Leslie L Robison; Peter D Inskip
Journal:  Radiat Res       Date:  2010-10-06       Impact factor: 2.841

5.  Thyroid Cancer after Childhood Exposure to External Radiation: An Updated Pooled Analysis of 12 Studies.

Authors:  Lene H S Veiga; Erik Holmberg; Harald Anderson; Linda Pottern; Siegal Sadetzki; M Jacob Adams; Ritsu Sakata; Arthur B Schneider; Peter Inskip; Parveen Bhatti; Robert Johansson; Gila Neta; Roy Shore; Florent de Vathaire; Lena Damber; Ruth Kleinerman; Michael M Hawkins; Margaret Tucker; Marie Lundell; Jay H Lubin
Journal:  Radiat Res       Date:  2016-04-29       Impact factor: 2.841

6.  Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study.

Authors:  Xuexia Wang; Can-Lan Sun; Lindsey Hageman; Kandice Smith; Purnima Singh; Sunil Desai; Douglas S Hawkins; Melissa M Hudson; Leo Mascarenhas; Joseph P Neglia; Kevin C Oeffinger; A Kim Ritchey; Leslie L Robison; Doojduen Villaluna; Wendy Landier; Smita Bhatia
Journal:  J Clin Oncol       Date:  2017-10-04       Impact factor: 44.544

7.  Polygenic Determinants for Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: The St Jude Lifetime Cohort Study (SJLIFE).

Authors:  Zhaoming Wang; Jinghui Zhang; Yutaka Yasui; Leslie L Robison; Qi Liu; Carmen L Wilson; John Easton; Heather Mulder; Ti-Cheng Chang; Michael C Rusch; Michael N Edmonson; Stephen V Rice; Matthew J Ehrhardt; Rebecca M Howell; Chimene A Kesserwan; Gang Wu; Kim E Nichols; James R Downing; Melissa M Hudson
Journal:  Clin Cancer Res       Date:  2018-10-26       Impact factor: 12.531

8.  Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations.

Authors:  Julius Gudmundsson; Patrick Sulem; Daniel F Gudbjartsson; Jon G Jonasson; Asgeir Sigurdsson; Jon T Bergthorsson; Huiling He; Thorarinn Blondal; Frank Geller; Margret Jakobsdottir; Droplaug N Magnusdottir; Sigurborg Matthiasdottir; Simon N Stacey; Oskar B Skarphedinsson; Hafdis Helgadottir; Wei Li; Rebecca Nagy; Esperanza Aguillo; Eduardo Faure; Enrique Prats; Berta Saez; Mariano Martinez; Gudmundur I Eyjolfsson; Unnur S Bjornsdottir; Hilma Holm; Kristleifur Kristjansson; Michael L Frigge; Hoskuldur Kristvinsson; Jeffrey R Gulcher; Thorvaldur Jonsson; Thorunn Rafnar; Hannes Hjartarsson; Jose I Mayordomo; Albert de la Chapelle; Jon Hrafnkelsson; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  Nat Genet       Date:  2009-02-06       Impact factor: 38.330

9.  Practical recommendations for reporting Fine-Gray model analyses for competing risk data.

Authors:  Peter C Austin; Jason P Fine
Journal:  Stat Med       Date:  2017-09-15       Impact factor: 2.373

10.  Association analyses identify 31 new risk loci for colorectal cancer susceptibility.

Authors:  Philip J Law; Maria Timofeeva; Ceres Fernandez-Rozadilla; Peter Broderick; James Studd; Juan Fernandez-Tajes; Susan Farrington; Victoria Svinti; Claire Palles; Giulia Orlando; Amit Sud; Amy Holroyd; Steven Penegar; Evropi Theodoratou; Peter Vaughan-Shaw; Harry Campbell; Lina Zgaga; Caroline Hayward; Archie Campbell; Sarah Harris; Ian J Deary; John Starr; Laura Gatcombe; Maria Pinna; Sarah Briggs; Lynn Martin; Emma Jaeger; Archana Sharma-Oates; James East; Simon Leedham; Roland Arnold; Elaine Johnstone; Haitao Wang; David Kerr; Rachel Kerr; Tim Maughan; Richard Kaplan; Nada Al-Tassan; Kimmo Palin; Ulrika A Hänninen; Tatiana Cajuso; Tomas Tanskanen; Johanna Kondelin; Eevi Kaasinen; Antti-Pekka Sarin; Johan G Eriksson; Harri Rissanen; Paul Knekt; Eero Pukkala; Pekka Jousilahti; Veikko Salomaa; Samuli Ripatti; Aarno Palotie; Laura Renkonen-Sinisalo; Anna Lepistö; Jan Böhm; Jukka-Pekka Mecklin; Daniel D Buchanan; Aung-Ko Win; John Hopper; Mark E Jenkins; Noralane M Lindor; Polly A Newcomb; Steven Gallinger; David Duggan; Graham Casey; Per Hoffmann; Markus M Nöthen; Karl-Heinz Jöckel; Douglas F Easton; Paul D P Pharoah; Julian Peto; Federico Canzian; Anthony Swerdlow; Rosalind A Eeles; Zsofia Kote-Jarai; Kenneth Muir; Nora Pashayan; Andrea Harkin; Karen Allan; John McQueen; James Paul; Timothy Iveson; Mark Saunders; Katja Butterbach; Jenny Chang-Claude; Michael Hoffmeister; Hermann Brenner; Iva Kirac; Petar Matošević; Philipp Hofer; Stefanie Brezina; Andrea Gsur; Jeremy P Cheadle; Lauri A Aaltonen; Ian Tomlinson; Richard S Houlston; Malcolm G Dunlop
Journal:  Nat Commun       Date:  2019-05-14       Impact factor: 14.919

View more
  1 in total

Review 1.  Genetic susceptibility to hereditary non-medullary thyroid cancer.

Authors:  Tina Kamani; Parsa Charkhchi; Afshan Zahedi; Mohammad R Akbari
Journal:  Hered Cancer Clin Pract       Date:  2022-03-07       Impact factor: 2.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.